A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

PHASE2RecruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions

OverweightObesity

Interventions

DRUG

NNC0662-0419

NNC0662-0419 will be administered subcutaneously.

DRUG

Placebo

Placebo matched to NNC0662-0419 will be administered subcutaneously.

Trial Locations (2)

RECRUITING

Celerion, Lincoln, Lincoln

NOT_YET_RECRUITING

Celerion, Phoenix, Tempe